83_FR_20169 83 FR 20081 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

83 FR 20081 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 88 (May 7, 2018)

Page Range20081-20081
FR Document2018-09659

Federal Register, Volume 83 Issue 88 (Monday, May 7, 2018) 
[Federal Register Volume 83, Number 88 (Monday, May 7, 2018)]
[Notices]
[Page 20081]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-09659]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel PHS, 2017-1 NIAID Topic 43 (Adjuvant 
Development).
    Date: May 30, 2018.
    Time: 10:30 a.m. to 12:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Thomas F. Conway, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, Room 3G51, National Institutes of Health, NIAID, 5601 
Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, 240-507-9685, 
thomas.conway@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: May 2, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-09659 Filed 5-4-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 88 / Monday, May 7, 2018 / Notices 20081 maintaining information, and disclosing data sources; to complete and review hours estimated for this ICR are and providing information; to train the collection of information; and to summarized in the table below. personnel and to be able to respond to transmit or otherwise disclose the a collection of information; to search information. The total annual burden TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Average Number of Total Number of Total burden per Form name responses per burden respondents responses response respondent hours (in hours) Rural Health Opioid Program Grant Performance Meas- ures ................................................................................... 10 1 10 11 110 Total .............................................................................. 10 ........................ 10 ........................ 110 Amy P. McNulty, Microbiology and Infectious Diseases Transfer and Development, 31 Center Acting Director, Division of the Executive Research, National Institutes of Health, HHS) Drive Room 4A29, MSC2479, Bethesda, Secretariat. Dated: May 2, 2018. MD 20892–2479; Telephone: +1–301– [FR Doc. 2018–09668 Filed 5–4–18; 8:45 am] Natasha M. Copeland, 435–4507; Fax: +1–301–594–3080; BILLING CODE 4165–15–P Program Analyst, Office of Federal Advisory Email: thalhamc@mail.nih.gov. Committee Policy. SUPPLEMENTARY INFORMATION: The [FR Doc. 2018–09659 Filed 5–4–18; 8:45 am] following represents the intellectual DEPARTMENT OF HEALTH AND BILLING CODE 4140–01–P property to be licensed under the HUMAN SERVICES prospective agreement: U.S. Provisional Patent Application National Institutes of Health DEPARTMENT OF HEALTH AND No. 61/488,671, filed May 20, 2011; PCT HUMAN SERVICES Application. No. PCT/US2012/028926, National Institute of Allergy and filed March 13, 2012; U.S. Patent No. Infectious Diseases; Notice of Closed National Institutes of Health 9,068,003, issued June 30, 2015; U.S. Meeting Patent No. 9,896,511, issued February Pursuant to section 10(d) of the Prospective Grant of Exclusive Patent 20, 2018; and U.S. Patent Application Federal Advisory Committee Act, as License: Antibodies Against TL1A, a No. 15/872,592, filed January 16, 2018, amended, notice is hereby given of the TNF-Family Cytokine, for the ‘‘Antibodies Against TL1A, a TNF- following meeting. Treatment and Diagnosis of Crohn’s Family Cytokine, for the Treatment and The meeting will be closed to the Disease, Ulcerative Colitis, Asthma, Diagnosis of Autoimmune Inflammatory public in accordance with the Psoriasis and Biliary Cirrhosis Diseases’’, NIH Reference No. E–073– provisions set forth in sections AGENCY: National Institutes of Health, 2011/0,1,2. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., With respect to persons who have an HHS. as amended. The contract proposals and obligation to assign their right, title and ACTION: Notice. the discussions could disclose interest to the Government of the United confidential trade secrets or commercial SUMMARY: The National Heart, Lung, and States of America, the patent rights in property such as patentable material, Blood Institute (‘‘NHLBI’’), an institute these inventions have been assigned to and personal information concerning of the National Institutes of Health; an the Government of the United States of individuals associated with the contract agency within the Department of Health America. proposals, the disclosure of which and Human Services, is contemplating The prospective exclusive license would constitute a clearly unwarranted the grant of an exclusive patent license territory may be worldwide and the invasion of personal privacy. to commercialize the invention(s) field of use may be limited to the use embodied in the intellectual property of Licensed Patent Rights for the Name of Committee: National Institute of following: ‘‘Development and Allergy and Infectious Diseases Special estate stated in the Summary Information section of this notice to commercialization of antibodies against Emphasis Panel PHS, 2017–1 NIAID Topic 43 (Adjuvant Development). Precision IBD, Inc., located in San TL1A for the treatment and diagnosis of Date: May 30, 2018. Diego, California, and incorporated Crohn’s Disease, Ulcerative Colitis, Time: 10:30 a.m. to 12:30 p.m. under the laws of Delaware. Asthma, Psoriasis and Biliary Cirrhosis’’ Agenda: To review and evaluate contract The subject technology is based on DATES: Only written comments and/or the use of antibodies against TL1A, a proposals. Place: National Institutes of Health, 5601 applications for a license which are TNF-Family cytokine, for the treatment Fishers Lane, Rockville, MD 20892 received by the NHLBI Office of and diagnosis of autoimmune (Telephone Conference Call). Technology Transfer and Development inflammatory diseases. Autoimmune Contact Person: Thomas F. Conway, Ph.D., on or before May 22, 2018 will be inflammatory diseases occur in greater Scientific Review Officer, Scientific Review considered. than five percent of the U.S. population. daltland on DSKBBV9HB2PROD with NOTICES Program, Division of Extramural Activities, Room 3G51, National Institutes of Health, ADDRESSES: Requests for copies of the Treatments generally include NIAID, 5601 Fishers Lane, MSC 9823, patent application, inquiries, and immunosuppressants or anti- Bethesda, MD 20892–9823, 240–507–9685, comments relating to the contemplated inflammatory drugs, which can have thomas.conway@nih.gov. exclusive license should be directed to: serious side effects. Recently, more (Catalogue of Federal Domestic Assistance Cristina Thalhammer-Reyero, Ph.D., specific immunomodulatory therapies Program Nos. 93.855, Allergy, Immunology, MBA, Senior Licensing and Patenting such as TNF-alpha antagonists have and Transplantation Research; 93.856, Manager, NHLBI Office of Technology been developed. In experiments with VerDate Sep<11>2014 17:38 May 04, 2018 Jkt 244001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\07MYN1.SGM 07MYN1


Document Created: 2018-05-05 02:48:46
Document Modified: 2018-05-05 02:48:46
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMay 30, 2018.
FR Citation83 FR 20081 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR